Investor Presentation 255 126 22 August 1, 2025 Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the "Company" or "Fulgent") about future events based on current views and assumptions. Examples of forward-looking statements made in this presentation include, a ...

Company Overview - Singular Genomics has raised approximately $450 million [10] - The company held $133 million in cash as of June 30, 2024 [10] - The company has approximately 195 employees [12] - The company has around 300 issued and pending patents [10, 12] Market Opportunity - The Next Generation Sequencing market is estimated at $7 billion in 2023, projected to reach $20 billion by 2030 [17] - The Spatial Sequencing market is estimated at $2 billion in 2023, projected to reach $11 billion by 2030, representing a 23% CAGR [19, 46] G4 Platform - The G4 platform offers flexibility with 1-4 flow cells and 16 lanes [28] - The G4 platform can achieve run times of 8-24 hours [28] - The G4 platform can produce up to 480 Gb output [28] G4X Platform - The G4X platform has a 40 cm² imaging area [77, 82] - The G4X platform offers high-throughput spatial sequencing with multiomic capabilities, including RNA, protein, and H&E [82]